These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 10747021)

  • 1. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis.
    Binétruy-Tournaire R; Demangel C; Malavaud B; Vassy R; Rouyre S; Kraemer M; Plouët J; Derbin C; Perret G; Mazié JC
    EMBO J; 2000 Apr; 19(7):1525-33. PubMed ID: 10747021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF.
    Jia H; Jezequel S; Löhr M; Shaikh S; Davis D; Soker S; Selwood D; Zachary I
    Biochem Biophys Res Commun; 2001 Apr; 283(1):164-73. PubMed ID: 11322784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor.
    Hetian L; Ping A; Shumei S; Xiaoying L; Luowen H; Jian W; Lin M; Meisheng L; Junshan Y; Chengchao S
    J Biol Chem; 2002 Nov; 277(45):43137-42. PubMed ID: 12183450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
    Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
    Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library.
    Zhu Z; Rockwell P; Lu D; Kotanides H; Pytowski B; Hicklin DJ; Bohlen P; Witte L
    Cancer Res; 1998 Aug; 58(15):3209-14. PubMed ID: 9699643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody.
    Zhu Z; Lu D; Kotanides H; Santiago A; Jimenez X; Simcox T; Hicklin DJ; Bohlen P; Witte L
    Cancer Lett; 1999 Mar; 136(2):203-13. PubMed ID: 10355750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165.
    Soker S; Gollamudi-Payne S; Fidder H; Charmahelli H; Klagsbrun M
    J Biol Chem; 1997 Dec; 272(50):31582-8. PubMed ID: 9395496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases.
    Meyer M; Clauss M; Lepple-Wienhues A; Waltenberger J; Augustin HG; Ziche M; Lanz C; Büttner M; Rziha HJ; Dehio C
    EMBO J; 1999 Jan; 18(2):363-74. PubMed ID: 9889193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action.
    Waltenberger J; Mayr U; Frank H; Hombach V
    J Mol Cell Cardiol; 1996 Jul; 28(7):1523-9. PubMed ID: 8841939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor.
    Dougher AM; Wasserstrom H; Torley L; Shridaran L; Westdock P; Hileman RE; Fromm JR; Anderberg R; Lyman S; Linhardt RJ; Kaplan J; Terman BI
    Growth Factors; 1997; 14(4):257-68. PubMed ID: 9386990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
    Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Nakatani T; Tsujinoue H; Fukui H
    Hepatology; 1999 Nov; 30(5):1179-86. PubMed ID: 10534339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor.
    Pan B; Li B; Russell SJ; Tom JY; Cochran AG; Fairbrother WJ
    J Mol Biol; 2002 Feb; 316(3):769-87. PubMed ID: 11866530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis.
    Keyt BA; Nguyen HV; Berleau LT; Duarte CM; Park J; Chen H; Ferrara N
    J Biol Chem; 1996 Mar; 271(10):5638-46. PubMed ID: 8621427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide.
    Bussolati B; Dunk C; Grohman M; Kontos CD; Mason J; Ahmed A
    Am J Pathol; 2001 Sep; 159(3):993-1008. PubMed ID: 11549592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis.
    Jia H; Lohr M; Jezequel S; Davis D; Shaikh S; Selwood D; Zachary I
    Biochem Biophys Res Commun; 2001 May; 283(2):469-79. PubMed ID: 11327725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor 165 (VEGF(165)) activities are inhibited by carboxymethyl benzylamide dextran that competes for heparin binding to VEGF(165) and VEGF(165).KDR Complexes.
    Hamma-Kourbali Y; Vassy R; Starzec A; Le Meuth-Metzinger V; Oudar O; Bagheri-Yarmand R; Perret G; Crépin M
    J Biol Chem; 2001 Oct; 276(43):39748-54. PubMed ID: 11514538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
    Brekken RA; Overholser JP; Stastny VA; Waltenberger J; Minna JD; Thorpe PE
    Cancer Res; 2000 Sep; 60(18):5117-24. PubMed ID: 11016638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased vascular endothelial growth factor 165 binding to kinase insert domain-containing receptor after infection of human endothelial cells by recombinant adenovirus encoding the Vegf(165) gene.
    Weisz A; Koren B; Cohen T; Neufeld G; Kleinberger T; Lewis BS; Flugelman MY
    Circulation; 2001 Apr; 103(14):1887-92. PubMed ID: 11294808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.